EX-10.10



  
 



 
 EXHIBIT 10.10 
 July 10, 2013 
 Scott Biller 
 26 Fletcher Avenue 
 Lexington, MA 02420 
 Dear Scott: 
 This letter agreement (this “Offer Letter”) is extended to you by Agios
Pharmaceuticals, Inc. (the “Company”), and it amends and restates the letter agreement (the “Old Offer Letter”), dated as of July 22, 2010, entered into between the Company and you. This Offer Letter supersedes the Old Offer
Letter in its entirety, and the Old Offer Letter shall no longer be of any force or effect. 
 As the Chief Scientific Officer of the Company,
you will receive a semi-monthly salary of $15,666.67, which is equivalent to $376,000.00 annually. All salary payments will be made in accordance with the Company’s regular payroll practice and will be subject to legally required tax
withholding. 
 Upon a Change of Control (as defined below), the vesting of the options, restricted stock and/or other stock-based equity awards
held by you (collectively “Shares”) shall be accelerated in part, such that 75% of the then unvested Shares shall immediately vest. The remaining 25% of the unvested Shares shall vest according to the schedule (i.e., with fewer Shares
vesting over the same time period) set forth in the applicable stock option agreement, restricted stock agreement or other similar equity agreement (collectively, “Equity Agreements”). If, upon or within 18-months following a Change of
Control, your employment is terminated by the Company without Cause (as defined below) or by you for Good Reason (as defined below), the vesting of your Shares shall accelerate in full, such that all of your Shares shall immediately vest as of the
date of such termination of employment. For purposes of this Offer Letter, “Change in Control” shall mean the sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger,
consolidation, sale of assets or otherwise (other than a transaction in which all or substantially all of the individuals and entities who were beneficial owners of the capital stock of the Company immediately prior to such transaction beneficially
own, directly or indirectly, more than 50% of the outstanding securities (on an as-converted to Common Stock basis) entitled to vote generally in the election of directors of the (i) resulting, surviving or acquiring corporation in such
transaction in the case of a merger, consolidation or sale of outstanding shares, or (ii) acquiring corporation in the case of a sale of assets). 
 You are eligible to participate in all of the Company’s benefits plans. In addition, as a member of the senior management team, you are entitled to any policies of the Company generally applicable to
members of senior management. You will accrue three weeks paid vacation each year and receive 11 paid holidays annually in accordance with the company holiday schedule. 
 38 Sidney Street, Suite 2 — Cambridge, MA 02139 
 Main: 617.649.8600 — Fax: 617.649.8799 
 www.agios.com 







 This Offer Letter is not intended to create or constitute an employment agreement or contract between you
and the Company. It is also important for you to understand that Massachusetts is an “at will” employment state. This means that you will have the right to terminate your employment relationship with the Company at any time for any reason.
Similarly, the Company will have the right to terminate its employment relationship with you at any time for any reason. 

Without otherwise limiting the “at-will” nature of your employment, in the event your employment is terminated at any time
by the Company without Cause or by you for Good Reason (a) the Company will continue to pay you your then-current base salary payable in accordance with the Company’s regular payroll practice for a period of twelve (12) months
commencing on the Payment Date (as defined below), (b) you will receive your annual incentive bonus to the extent otherwise payable during such 12-month period payable in a lump sum when annual incentive bonuses are paid to other members of
senior management of the Company but, in any event, no later than March 15 of the year following the year in which the Board of Directors (or its designee) approves the payment of such bonuses to members of senior management of the Company,
(c) you will be entitled to 12 months of continuation of health and dental insurance consistent with the current plans provided by the Company and payable in accordance with the Company’s regular payroll practice with respect to benefits
and (d) if such termination occurs prior to a Change of Control, the vesting of your Shares shall be accelerated in part, such that a number of Shares equal to 25% of the original number of Shares subject to each of your Equity Agreements shall
immediately vest (or if the number of unvested Shares subject to any such Equity Agreement is less than 25% of the original award subject to such Equity Agreement, then all remaining unvested Shares subject to such Equity Agreement shall immediately
become fully vested). No severance payments or acceleration of vesting shall be paid under this Offer Letter unless you first execute and do not revoke a waiver and release within 45 days following the date of termination, which provides for a
release of any and all claims that you have or might have against the Company. The severance payments and acceleration of vesting shall be paid or commence on the first payroll period following the date the waiver and release becomes effective
(the “Payment Date”). Notwithstanding the foregoing, if the 45th day following the date of termination occurs in the calendar year following the calendar year of the termination, then the Payment Date shall be no earlier than January 1 of such subsequent calendar
year. 
 For the purposes of this Offer Letter, the Company shall have “Cause” for termination upon: (a) a finding by the
Company’s Board of Directors, in its reasonable discretion, that you have engaged in dishonesty, misconduct or gross negligence; (b) the conviction of you, or the entry of a pleading of guilty or nolo contendere by you to, any crime
involving moral turpitude or any felony; or (c) a material breach of any agreement between you and the Company. 
 For
purposes of this Offer Letter, “Good Reason” shall mean the occurrence of any of the following events without your prior written consent: 
  

	 	(a)	a material diminution in your base compensation; 









	 	(b)	a material diminution in your authority, duties or responsibilities (this determination will include an analysis of whether you maintain at least the same level, scope
and type of duties and responsibilities with respect to the management, strategy, operations and business of the Company); or 

  

	 	(c)	a material change in geographic location at which you perform services (if your new one-way commute is more than thirty five (35) miles greater than your one-way
commute prior to the change in your principal work location, regardless of whether you receive an offer of relocation benefits, such change shall be deemed material hereunder); 

 provided, however, that no such event or condition shall constitute Good Reason unless (x) you give the Company a written notice of termination for Good Reason not more than
30 days after the initial existence of the condition, (y) the grounds for termination (if susceptible to correction) are not corrected by the Company within 30 days of its receipt of such notice and (z) your termination of
employment occurs within two months following the Company’s receipt of such notice. 
 Any severance payments or benefits provided to you
pursuant to this Offer Letter shall begin only after the date of your “separation from service” (within the meaning of Section 409A of the Internal Revenue Code of 1986 (as amended or replaced) (the “Code”), which occurs on
or after date of the termination of your employment, and shall be subject to the following provisions: 
 (i) It is intended
that each installment of the severance payments and benefits shall be treated as a separate “payment” for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of
any such payments or benefits except to the extent specifically permitted or required by Section 409A. 
 (ii) If, as of
the date of your “separation from service” from the Company, you are not a “specified employee” (within the meaning of Section 409A), then each installment of the severance and benefits payments shall be made on the dates
and terms set forth in this Offer Letter. 
 (iii) If, as of the date of your “separation from service” from the
Company, you are a “specified employee” (within the meaning of Section 409A), then: 
 (A) Each installment of
the severance payments and benefits, that, in accordance with the dates and terms set forth in this Offer Letter, will in all circumstances, regardless of when the “separation from service” occurs, be paid within the short-term deferral
period (as defined under Section 409A) shall be treated as a “short-term deferral” within the meaning of Treasury Regulation Section 1.409A-l(b)(4) to the maximum extent permissible under Section 409A and shall be made on
the dates and terms set forth in this Offer Letter; and 
 (B) Each installment of the severance payments and benefits that is
not described in clause (iii)(A) above and that would, absent this clause (B), be paid 







 
within the six-month period following your “separation from service” from the Company shall not be paid until the date that is six months and one day after such “separation from
service” (or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following your “separation
from service” and any subsequent installments, if any, being paid in accordance with the dates and terms set forth in this Offer Letter; provided, however, that the preceding provisions of this clause (B) shall not apply to any installment
of severance payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation
1.409A-l(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1 (b)(9)(iii) must be paid no later than the last day of your
second taxable year following the taxable year in which the “separation from service” occurs. 
 (iv) The
determination of whether and when your “separation from service” from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-I(h). Solely for
purposes of this paragraph (iv), “Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code. 

(v) All reimbursements and in-kind benefits provided under this Offer Letter shall be made or provided in accordance with the
requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during your
lifetime (or during a shorter period of time specified in this Offer Letter), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year,
(iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or
exchange for any other benefit. 
 (vi) Notwithstanding any other provision of this Offer Letter, the Company shall have no
liability to you or to any other person if any provisions of this Offer Letter that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant. 

[Remainder of Page Intentionally Left Blank] 







 Please acknowledge your agreement to the foregoing terms and conditions of your employment by returning a
signed copy of this Offer Letter. 
 Best regards, 
 /s/ Dr. David Schenkein, M.D. 
 Dr. David Schenkein, M.D. 

Chief Executive Officer 
 Agios Pharmaceuticals,
Inc. 
 ACKNOWLEDGED AND AGREED: 

Signature: 
  

					
			
	/s/ Scott Biller	 		 	July 10, 2013
	Scott Biller	 		 	Date